Priced like the old business, running like a new one: management is redirecting the call away from the metric investors
The model's full reasoning — Q4 2021 call → NOWe need to determine if management repeatedly redirects attention away from the conventional measure and toward a different part of the business that is already earning, and indicates the record hasn't caught up. Let's analyze the transcript. The company is SOPHiA GENETICS, a healthcare data platform. The conventional yardstick likely is clinical customer adoption, platform analyses, revenue growth. But management might be redirecting to biopharma or HRD or CarePath. Look for management's own words. Jurgi talks about six pillars. He mentions biopharma as a massive opportunity. Peter Casasanto is brought in as Chief BioPharma Officer. He says "Biopharma represents a large opportunity for us given our cloud-based architecture..." He talks about HRD solution, AstraZeneca partnership. But is he saying that the conventional yardstick (clinical customers, analyses) is no longer the right thing? He doesn't explicitly set aside the clinical business. He says "Among the many exciting opportunities we see in the biopharma arena, SOPHiA's HRD solution stands near the top." That's a highlight, not a redirection. Ross talks about financial results, revenue growth, net dollar retention, etc. He doesn't set aside any metric. Jurgi in closing remarks: "Our six pillars remain our foundation to drive growth and value creation." No redirection. Question: Does management repeatedly redirect attention away from the measure or storyline by which the company is conventionally judged? The conventional measure might be clinical customer adoption and platform analyses. But management doesn't say "don't look at that, look at biopharma." They talk about biopharma as one of the pillars. They also talk about CarePath, HRD, etc. But they don't set aside the conventional yardstick. They still discuss revenue, customers, analyses, etc. They don't say the old metric is no longer relevant. Also, the different part (biopharma) is described as already earning? Peter says "we are having conversations" and "these conversations lead to more proposals, more proposals lead to more bookings." That's prospective. He doesn't say it's already contributing significant revenue. He says "While we can't give the revenue mix today" - so it's not yet reflected. But is it already earning? He mentions AstraZeneca partnership, but that's a partnership, not necessarily revenue.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
SPT · Q2 2023 → YESThe question is whether management repeatedly redirects attention away from the conventional measure toward a different part of the business that's already earning today, and indicates that this diffe...YES The transcript shows management repeatedly reframing away from the conventional total ARR/revenue growth metric (which is being distorted by unpredictable low-end non-core ARR) toward the higher-quality up-market/enterprise segment that is already delivering record new business ACVs, 50%+ YoY growth, and 43% of 2023 ARR. They explicitly set the low-end aside by removing it from forecasts and modeling to give “greatest visibility,” note that Q2 ARR growth will be the lowest pace of the year because of this change, and indicate the reported figures still reflect the old mix while the new up-market story is already earning today (with Tagger adding further upside not yet reflected). This creates the coherent posture of redirecting attention from the headline growth number outsiders watch to the part of the business that is already producing real results.
WD · Q2 2022 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly reframing the discussion away from the conventional multifamily agency lender yardstick (origination volumes, GSE lending, MSR-driven EPS) toward the diversified services and asset-management businesses that are already generating substantial cash revenue and EBITDA today. They explicitly set the old metric aside by introducing adjusted EPS to “strip out non-cash mortgage servicing rights,” highlight the shift from “lending-centric” to “broader technology-enabled financial services,” and note that segment results now provide “more transparency into our operating structure.” They point to debt brokerage, property sales, SAM (Alliant, Zelman), small-balance lending, and appraisals as the new earning engines, describing their concrete contributions (e.g.
CALX · Q1 2023 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly framing the company as operating in a "new market" centered on platforms, clouds, and managed services—distinct from the legacy hardware/cyclical model—while highlighting real earnings from these areas (e.g., 988 BSPs deploying platforms, 865 cloud customers, 334 with 41 new managed services in Q1, record Intelligent Access EDGE revenue). They indicate this is already producing revenue and customer adoption but remains early-stage ("this is the beginning," "early stage of where we are in this new market"), with reported results still reflecting the prior hardware-focused picture.